ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum
ADMA Biologics' Q2 earnings and revenue beat can be attributed to Asceniv growth. However, shares fall 7.4% in after-hours trading.
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - ADMA Biologics ( NASDAQ:ADMA ) , Airbnb ( NASDAQ:ABNB )
U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Thursday. Shares of Redwire Corporation RDW fell sharply in pre-market trading after the company reported worse-than-expected second-quarter financial results and cut its FY25 sales guidance.
Adma Biologics ( ADMA ) Q2 Revenue Up 14%
Adma Biologics ( NASDAQ:ADMA ) , a plasma-derived biologics manufacturer focused on immunotherapies, released its earnings for Q2 2025 on August 6, 2025. The quarter showed continued revenue growth, with GAAP total revenue of $122.0 million, with total revenue ( GAAP ) reaching $122.0 million, ...
Adma Biologics ( ADMA ) Q2 Earnings and Revenues Beat Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of +7.14% and +0.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Is ADMA Biologics Gaining or Losing Market Support? - ADMA Biologics ( NASDAQ:ADMA )
ADMA Biologics's ADMA short percent of float has fallen 10.9% since its last report. The company recently reported that it has 14.47 million shares sold short, which is 7.44% of all regular shares that are available for trading.
Adma Biologics ( ADMA ) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Adma Biologics (ADMA) closed at $18.59, marking a +1.81% move from the previous day.
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025
Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET Conference Call Scheduled for August 6, 2025, at 4:30 p.m. ET ...
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 - ADMA Biologics ( NASDAQ:ADMA )
RAMSEY, N.J. and BOCA RATON, Fla., July 30, 2025 ( GLOBE NEWSWIRE ) -- ADMA Biologics, Inc.
Adma Biologics ( ADMA ) Rises As Market Takes a Dip: Key Facts
The latest trading day saw Adma Biologics (ADMA) settling at $18.26, representing a +1.44% change from its previous close.
Brokers Suggest Investing in Adma Biologics ( ADMA ) : Read This Before Placing a Bet
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Adma Biologics ( ADMA ) Exceeds Market Returns: Some Facts to Consider
Adma Biologics (ADMA) concluded the recent trading session at $17.13, signifying a +2.39% move from its prior day's close.
Adma Biologics ( ADMA ) Declines More Than Market: Some Information for Investors
In the most recent trading session, Adma Biologics (ADMA) closed at $17.98, indicating a -3.75% shift from the previous trading day.
Adma Biologics ( ADMA ) Outperforms Broader Market: What You Need to Know
Adma Biologics (ADMA) concluded the recent trading session at $18.34, signifying a +2.98% move from its prior day's close.
Wall Street Bulls Look Optimistic About Adma Biologics ( ADMA ) : Should You Buy?
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Is ADMA Biologics Gaining or Losing Market Support? - ADMA Biologics ( NASDAQ:ADMA )
ADMA Biologics's ADMA short percent of float has fallen 3.53% since its last report. The company recently reported that it has 13.81 million shares sold short, which is 7.1% of all regular shares that are available for trading.
Adma Biologics ( ADMA ) Stock Drops Despite Market Gains: Important Facts to Note
Adma Biologics (ADMA) closed at $18.16 in the latest trading session, marking a -1.3% move from the prior day.
Implied Volatility Surging for ADMA Biologics Stock Options
Investors need to pay close attention to ADMA stock based on the movements in the options market lately.
Will Strong Asceniv Sales Drive ADMA Biologics Further?
ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.
Here's Why Adma Biologics ( ADMA ) Fell More Than Broader Market
Adma Biologics (ADMA) closed the most recent trading day at $17.74, moving 2.15% from the previous trading session.
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
ADMA surges on soaring Asceniv demand and eyes pediatric label expansion to widen its immunodeficiency treatment reach.
Is Invesco S&P SmallCap Quality ETF ( XSHQ ) a Strong ETF Right Now?
Smart Beta ETF report for ...
ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?
ADMA rises on strong Asceniv demand and boosted 2025-2026 guidance. However, valuation warrants investor caution.
Should Invesco S&P SmallCap Quality ETF ( XSHQ ) Be on Your Investing Radar?
Style Box ETF report for ...
How Is The Market Feeling About ADMA Biologics? - ADMA Biologics ( NASDAQ:ADMA )
ADMA Biologics's ADMA short percent of float has risen 8.03% since its last report. The company recently reported that it has 13.33 million shares sold short, which is 6.86% of all regular shares that are available for trading.
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?
At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.
Are Options Traders Betting on a Big Move in ADMA Biologics Stock?
Investors need to pay close attention to ADMA Biologics stock based on the movements in the options market lately.
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates
PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
Puma Biotechnology beats on first-quarter 2025 earnings and sales. Stock rises in after-hours trading ...
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?
ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025. We recommend the stock to prospective investors.
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - ADMA Biologics ( NASDAQ:ADMA ) , argenx ( NASDAQ:ARGX )
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 300 points on Thursday. The Dow traded up 1.50% to 41,729.20 while the NASDAQ gained 1.91% to 18,076.43. The S&P 500 also rose, gaining, 1.44% to 5,712.61. In trading on Thursday, health care stocks fell by ...
Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains
VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Adma Biologics ( ADMA ) Misses Q1 Earnings and Revenue Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of -12.50% and 3.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y
RARE reports weaker-than-expected first-quarter results, as earnings and revenues miss estimates despite a year-over-year increase in product sales.
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up
NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.
CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks
CRSP reports wider-than-expected first-quarter loss. Revenues also miss estimates. Stock tanks 12%.
Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down
KRYS reports disappointing first-quarter 2025 results, with both earnings and sales missing estimates. Shares down.
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall
Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025. Stock down.
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened
Vertex reports weaker-than-expected first-quarter 2025 results. The company tightens its total revenue guidance for 2025.
Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised
ZTS reports better-than-expected first-quarter results as earnings and revenues surpass estimates. Management raises 2025 guidance.
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Axsome reports better-than-expected first quarter 2025 results. Net product revenues surge year over year on strong Auvelity sales.
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates
Recursion Pharmaceuticals stock falls due to weaker-than-expected first-quarter results, along with the abandonment of certain key pipeline programs.
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Adma Biologics ( ADMA ) Increases Yet Falls Behind Market: What Investors Need to Know
Adma Biologics (ADMA) concluded the recent trading session at $23.52, signifying a +1.07% move from its prior day's close.
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
Amicus' first-quarter 2025 earnings and sales miss estimates. Shares decline.
